Examples of 'denosumab' in a sentence
Meaning of "denosumab"
denosumab (noun): A pharmaceutical drug used for the treatment of osteoporosis and other conditions. It is commonly used in the context of medicine and healthcare
Show more definitions
- A drug (trademark Prolia and Xgera) that is a genetically engineered monoclonal antibody that reduces bone resorption and increases bone mass by inhibiting osteoclast formation and function and that is administered by injection to prevent fractures associated with osteoporosis and malignant tumors of bone and to treat hypercalcemia associated with various cancers.
How to use "denosumab" in a sentence
Basic
Advanced
denosumab
It is unknown whether denosumab is excreted in human milk.
Denosumab is known to be administered by the subcutaneous route.
The pharmacokinetics of denosumab were not affected by race.
Xgeva contains the active substance denosumab.
The genotoxic potential of denosumab has not been evaluated.
The most common are bisphosponates and denosumab.
She continues on the denosumab treatments.
The medicine contains the active substance denosumab.
Another medicine containing denosumab a bisphosphonate.
Most preferably the human antibody is adalimumab or denosumab.
The pharmacokinetics of denosumab is not expected to be affected by hepatic impairment.
No data are available on the effect of denosumab on human fertility.
Discontinuation of denosumab is associated with a rebound increase in bone turnover.
We also talked about the denosumab treatments.
Denosumab is contraindicated in people with low blood calcium levels.
See also
The active substance is denosumab.
It is unlikely that denosumab exhibits any clinically relevant interactions.
A significant change was observed on both markers after denosumab administration p.
Denosumab is a monoclonal antibody that slows down bone resorption.
Another medicine containing denosumab.
Denosumab may be an option if a woman can not tolerate bisphosphonates.
Bisphosphonates and denosumab may be of use for the bone lesions.
Denosumab also showed a moderate tendency toward causing infection.
The human monoclonal antibody denosumab showed similar adverse effects.
Denosumab is a medicine used to prevent or treat certain bone problems.
Quite many patients have thus switched from bisphosphonates to denosumab.
Denosumab may be given as a treatment for hypercalcemia when bisphosphonates are no longer working.
Xgeva is a solution for injection that contains the active substance denosumab.
Denosumab is a fully human monoclonal antibody that was developed using transgenic mouse technology.
Prolia is a solution for injection that contains the active substance denosumab.
Denosumab has been found successful in reducing bone pain and decreasing tumor growth.
Invasive dental procedures should be avoided while the patient is being treated with denosumab.
Denosumab is administered by your doctor as an injection under the skin every six months.
This medication guide provides information about the Xgeva brand of denosumab.
Denosumab is another treatment that may be used if a cancer has spread to the bones.
You should not take Prolia together with another medicine containing denosumab.
Denosumab is an inhibitor of osteoclastic bone resorption via inhibition of RANKL.
Our study is the first that evaluated the use of denosumab in children with CP.
Denosumab inhibits this maturation of osteoclasts by binding to and inhibiting RANKL.
You should not take XGEVA together with other medicines containing denosumab or bisphosphonates.
Prior art therapy with Denosumab would typically involve subcutaneous treatment.
Hiligsmann and Reginster have carried out a costeffectiveness assessment comparing denosumab with no drug treatment.
Denosumab is the first RANKL inhibitor to be approved by the FDA.
Patients receiving bisphosphonates or denosumab should also be taking calcium and vitamin D supplementation.
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
In clinical studies, neutralising antibodies have not been observed for denosumab.
Amgen manufactures denosumab and Eli Lilly manufactures teriparatide.
Pre-existing hypocalcemia should be corrected before denosumab treatment is initiated.
Stop treatment with denosumab at least 3 weeks prior to any dental procedures.
In clinical trials, musculoskeletal pain was very common in both denosumab and placebo groups.
